[go: up one dir, main page]

WO2004085665A3 - Nucleic acid ligand to b. anthracis protective antigen - Google Patents

Nucleic acid ligand to b. anthracis protective antigen Download PDF

Info

Publication number
WO2004085665A3
WO2004085665A3 PCT/US2003/020844 US0320844W WO2004085665A3 WO 2004085665 A3 WO2004085665 A3 WO 2004085665A3 US 0320844 W US0320844 W US 0320844W WO 2004085665 A3 WO2004085665 A3 WO 2004085665A3
Authority
WO
WIPO (PCT)
Prior art keywords
protective antigen
nucleic acid
anthracis protective
acid ligand
bacillus anthracis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/020844
Other languages
French (fr)
Other versions
WO2004085665A2 (en
Inventor
Chareles Wilson
David Epstein
Sharon T Cload
Nicholas Marsh
Nobuko Hamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archemix Corp
Original Assignee
Archemix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp filed Critical Archemix Corp
Priority to AU2003304015A priority Critical patent/AU2003304015A1/en
Publication of WO2004085665A2 publication Critical patent/WO2004085665A2/en
Anticipated expiration legal-status Critical
Publication of WO2004085665A3 publication Critical patent/WO2004085665A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Biochemistry (AREA)
  • Composite Materials (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Materials and methods are provided to treat subjects exposed to bacillus anthracis protective antigen to prevent virulence of anthrax disease caused by bacillus anthracis. Materials and methods are also provided to detect the presence of bacillus anthracis protective antigen in a sample.
PCT/US2003/020844 2002-06-19 2003-06-19 Nucleic acid ligand to b. anthracis protective antigen Ceased WO2004085665A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003304015A AU2003304015A1 (en) 2002-06-19 2003-06-19 Nucleic acid ligand to b. anthracis protective antigen

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US39021402P 2002-06-19 2002-06-19
US60/390,214 2002-06-19
US44597703P 2003-02-07 2003-02-07
US60/445,977 2003-02-07
US45325903P 2003-03-10 2003-03-10
US60/453,259 2003-03-10
US46293003P 2003-04-15 2003-04-15
US60/492,930 2003-08-06

Publications (2)

Publication Number Publication Date
WO2004085665A2 WO2004085665A2 (en) 2004-10-07
WO2004085665A3 true WO2004085665A3 (en) 2005-12-29

Family

ID=34139803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020844 Ceased WO2004085665A2 (en) 2002-06-19 2003-06-19 Nucleic acid ligand to b. anthracis protective antigen

Country Status (2)

Country Link
AU (1) AU2003304015A1 (en)
WO (1) WO2004085665A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010073257A1 (en) * 2008-12-26 2010-07-01 Manpreet Kaur An immunodominant b-cell epitope based protein vaccine against anthrax and method of preparation thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRADLEY K.A.: "Identification of the cellular reception for anthrax toxin", NATURE, vol. 414, November 2001 (2001-11-01), pages 225 - 229, XP002228301 *
BRUNO J.G.: "In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection", BIOSENS.BIOELECTRON., vol. 14, May 1999 (1999-05-01), pages 457 - 464, XP002276780 *
HAMAGUCHI N.: "Aptamer Beacons for the Direct Detection of Proteins", ANALYTICAL CHEMISTRY, vol. 294, June 2001 (2001-06-01), pages 126 - 131, XP002240692 *
MOUREZ M.: "Designing a polyvalent inhibitor of anthrax toxin", NATURE BIOTECHNOLOGY, vol. 19, October 2001 (2001-10-01), pages 958 - 961, XP002228104 *
SELLMAN B.R.: "Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax", SCIENCE, vol. 292, April 2001 (2001-04-01), pages 695 - 697, XP002992368 *

Also Published As

Publication number Publication date
AU2003304015A1 (en) 2004-10-18
WO2004085665A2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
WO2001042504A3 (en) Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
EP1625386B8 (en) Analyte concentration detection devices and methods
WO2001018252A3 (en) Methods for disease detection
EP2267136A3 (en) Glyphosate tolerant alfalfa events and methods for detection thereof
ATE330038T1 (en) NUCLEIC ACID BIOSENSOR
WO2004083816A3 (en) Loss of heterozygosity of the dna markers in the 12q22-23 region
AU2003275112A1 (en) System, method and computer program product for subsurface contamination detection and analysis
EP1951860A4 (en) Portable preparation, analysis, and detection apparatus for nucleic acid processing
WO2005103979A3 (en) Gathering data concerning publication usage and exposure to products and/or presence in commercial establishment
WO2001042502A3 (en) Methods for disease detection
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2005065241A3 (en) Smmr (small molecule metabolite reporters) for use as in vivo glucose biosensors
WO2003008622A3 (en) Exponential nucleic acid amplification using nicking endonucleases
AU2002366046A1 (en) Nucleic acid probes and methods to detect and/or quantify nucleic acid analytes
AU2002363447A1 (en) Neuromuscular disease detection using disease specific evoked neuromuscular response analysis
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
AU2002359776A8 (en) Conductimetric biosensor device, method and system
EP1435776A4 (en) ANTICANCER VACCINE, DIAGNOSTIC METHODS AND REAGENTS
WO2005049856A3 (en) Methods and apparatus for the rapid detection of microorganisms collected from infected sites
WO2004022006A3 (en) Methods of diagnosing cervical cancer
AU2003281805A1 (en) Combined chemical/biological agent detection system and method utilizing mass spectrometry
WO2004011906A3 (en) Diagnostic system for differentiating sputum from saliva
WO2004113574A3 (en) Methods for disease screening
AP2316A (en) Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same.
WO2004085665A3 (en) Nucleic acid ligand to b. anthracis protective antigen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP